Oncovista Innovative Therapies Stock Equity Positions Weight
| OVIT Stock | USD 0.0001 0.00 0.00% |
OncoVista Innovative Therapies fundamentals help investors to digest information that contributes to OncoVista Innovative's financial success or failures. It also enables traders to predict the movement of OncoVista Pink Sheet. The fundamental analysis module provides a way to measure OncoVista Innovative's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to OncoVista Innovative pink sheet.
OncoVista |
OncoVista Innovative Therapies Company Equity Positions Weight Analysis
OncoVista Innovative's Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.
More About Equity Positions Weight | All Equity Analysis
Stock Percentage | = | % of Equities | in the fund |
Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.
| Competition |
According to the company disclosure, OncoVista Innovative Therapies has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
OncoVista Fundamentals
| Return On Asset | -23.58 | |||
| Current Valuation | 852.92 K | |||
| Shares Outstanding | 23.56 M | |||
| Price To Earning | (0.12) X | |||
| Price To Book | 26.09 X | |||
| EBITDA | (3.4 M) | |||
| Net Income | (2.54 M) | |||
| Cash And Equivalents | 61.27 K | |||
| Total Debt | 479.3 K | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.28) X | |||
| Cash Flow From Operations | (232.38 K) | |||
| Earnings Per Share | (0.15) X | |||
| Beta | -51.97 | |||
| Market Capitalization | 558.34 K | |||
| Total Asset | 12.51 K | |||
| Retained Earnings | (27.6 M) | |||
| Working Capital | (5.89 M) | |||
| Current Asset | 61 K | |||
| Current Liabilities | 5.95 M | |||
| Net Asset | 12.51 K |
About OncoVista Innovative Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OncoVista Innovative Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OncoVista Innovative using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OncoVista Innovative Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for OncoVista Pink Sheet Analysis
When running OncoVista Innovative's price analysis, check to measure OncoVista Innovative's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoVista Innovative is operating at the current time. Most of OncoVista Innovative's value examination focuses on studying past and present price action to predict the probability of OncoVista Innovative's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoVista Innovative's price. Additionally, you may evaluate how the addition of OncoVista Innovative to your portfolios can decrease your overall portfolio volatility.